EP Patent

EP4248969A1 — Use of pitolisant for treating severe fatigue

Assigned to Bioprojet SC · Expires 2023-09-27 · 3y expired

What this patent protects

The present invention concerns the treatment of severe fatigue (SF), in particular in patients suffering from narcolepsy, comprising the administration of pitolisant or its pharmaceutically acceptable salts, such as the monohydrochloride salt at high doses.

USPTO Abstract

The present invention concerns the treatment of severe fatigue (SF), in particular in patients suffering from narcolepsy, comprising the administration of pitolisant or its pharmaceutically acceptable salts, such as the monohydrochloride salt at high doses.

Drugs covered by this patent

Patent Metadata

Patent number
EP4248969A1
Jurisdiction
EP
Classification
—
Expires
2023-09-27
Drug substance claim
No
Drug product claim
No
Assignee
Bioprojet SC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.